Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

222 Press Releases
DateTitleCompany
23 May 12 €100,000 In Reward Donations for Projects Fundraising to Prevent Atrial Fibrillation-Related Strokes Boehringer Ingelheim,
Published by
Business Wire
22 May 12 Boehringer Ingelheim Announces Positive Phase II Results for Once-Daily Tiotropium in Asthma Boehringer Ingelheim,
Published by
Business Wire
22 May 12 One million signatures needed to call upon World Health Organization to save lives through education and improved management of atrial fibrillation Boehringer Ingelheim,
Published by
Business Wire
22 May 12 Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD Boehringer Ingelheim,
Published by
Business Wire
17 May 12 Pivotal study on afatinib may challenge current standard first line treatment1 for lung cancer patients with EGFR mutations Boehringer Ingelheim,
Published by
Business Wire
09 May 12 New for pharmacists: online COPD resource at the click of a button Boehringer Ingelheim Ltd and Pfizer Ltd,
Published by
Porter Novelli
29 Apr 12 Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals Boehringer Ingelheim GmbH,
Published by
Business Wire
20 Apr 12 Media Alert: Pivotal Phase III results for afatinib* in lung cancer to be presented at ASCO 2012 Boehringer Ingelheim,
Published by
Business Wire
19 Apr 12 Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*) Boehringer Ingelheim
19 Apr 12 Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*) Boehringer Ingelheim,
Published by
Business Wire
19 Apr 12 First Ever Data Investigating Interferon-Free Treatment in Hepatitis C Patients Who Have Liver Cirrhosis Shows High Viral Cure Rate Boehringer Ingelheim,
Published by
Business Wire
14 Apr 12 More time, more lives: New authorisation to make life-saving treatment available to ischaemic stroke patients presenting within 4.5hrs after the onset of stroke symptoms Boehringer Ingelheim,
Published by
Business Wire
05 Apr 12 New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients Boehringer Ingelheim,
Published by
Business Wire
29 Mar 12 Pradaxa® reduced to £2.20 a day Boehringer Ingelheim
19 Mar 12 Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK1 Boehringer Ingelheim,
Published by
Business Wire
09 Mar 12 Boehringer Ingelheim expands capabilities in biopharmaceutical process science Boehringer Ingelheim
27 Feb 12 Free First Aid Training for Berkshire Kids Boehringer Ingelheim Limited
10 Feb 12 Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product supply Boehringer Ingelheim
27 Jan 12 Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply Boehringer Ingelheim,
Published by
PharmiWeb.com
08 Nov 11 BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients 1,2 Boehringer Ingelheim,
Published by
Business Wire
07 Nov 11 Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment 1 Boehringer Ingelheim,
Published by
Business Wire
27 Oct 11 Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe Boehringer Ingelheim
21 Oct 11 New Boehringer Ingelheim Hepatitis C Data to Be Presented at AASLD Boehringer Ingelheim GmbH,
Published by
Business Wire
06 Oct 11 Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors Gilead Sciences Inc. and Boehringer Ingelheim,
Published by
Business Wire
27 Sep 11 BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events Boehringer Ingelheim GmbH,
Published by
Business Wire
21 Sep 11 Trajenta(linagliptin) launches in the UK for adults with type 2 diabetes mellitus Boehringer Ingelheim and Eli Lilly and Company,
Published by
PharmiWeb.com
21 Sep 11 Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD Boehringer Ingelheim,
Published by
Business Wire
16 Sep 11 New data for once-daily linagliptin show durable efficacy over two years Boehringer Ingelheim,
Published by
Business Wire
30 Aug 11 Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib* Boehringer Ingelheim,
Published by
PharmiWeb.com
29 Aug 11 Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib* Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.